{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["gilteritinib"]],"indication":"ALK-positive stage IV non-small cell lung cancer","name":"NCT06225427","nct_id":"NCT06225427","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06225427. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive gilteritinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiography at screening and blood sample collection, CT scan and MRI at screening and on study. Additionally, patients may undergo a tumor biopsy pre-treatment and at end of treatment.","label":"Treatment (gilteritinib)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-05","type":"ESTIMATED"},"conditions":["Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":{"count":30,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biopsy","otherNames":["BIOPSY_TYPE","Bx"],"type":"PROCEDURE"},{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","CT","CT Scan","tomography"],"type":"PROCEDURE"},{"name":"Echocardiography","otherNames":["EC"],"type":"PROCEDURE"},{"name":"Gilteritinib","otherNames":["ASP-2215","ASP2215"],"type":"DRUG"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-06-26","lead_sponsor":"University of Michigan Rogel Cancer Center","official_title":"Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of adverse events","timeFrame":"Up to 30 days after last dose of gilteritinib"},{"measure":"Dose-limiting toxicities (DLT)","timeFrame":"Cycle 1 day 1 up to cycle 2 day 1 (each cycle is 21 days)"}],"references":[],"start_date":{"date":"2024-07-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Gilteritinib for the Treatment of ALK NSCLC","url":"https://clinicaltrials.gov/study/NCT06225427"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06225427"}